Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRRK POWR Grades
- Sentiment is the dimension where SRRK ranks best; there it ranks ahead of 61.51% of US stocks.
- The strongest trend for SRRK is in Stability, which has been heading up over the past 179 days.
- SRRK's current lowest rank is in the Momentum metric (where it is better than 14.49% of US stocks).
SRRK Stock Summary
- Of note is the ratio of SCHOLAR ROCK HOLDING CORP's sales and general administrative expense to its total operating expenses; just 11.21% of US stocks have a lower such ratio.
- With a price/sales ratio of 16.79, SCHOLAR ROCK HOLDING CORP has a higher such ratio than 93.18% of stocks in our set.
- As for revenue growth, note that SRRK's revenue has grown 104.59% over the past 12 months; that beats the revenue growth of 92.11% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to SCHOLAR ROCK HOLDING CORP, a group of peers worth examining would be CRNX, ARBE, AEVA, INVZ, and ARCT.
- SRRK's SEC filings can be seen here. And to visit SCHOLAR ROCK HOLDING CORP's official web site, go to scholarrock.com.
SRRK Valuation Summary
- In comparison to the median Healthcare stock, SRRK's price/sales ratio is 704.76% higher, now standing at 16.9.
- Over the past 57 months, SRRK's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for SRRK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SRRK | 2023-01-30 | 16.9 | 2.1 | -4.8 | -4.3 |
| SRRK | 2023-01-27 | 17.6 | 2.2 | -5.0 | -4.5 |
| SRRK | 2023-01-26 | 17.4 | 2.2 | -4.9 | -4.4 |
| SRRK | 2023-01-25 | 17.1 | 2.2 | -4.9 | -4.4 |
| SRRK | 2023-01-24 | 17.6 | 2.2 | -5.0 | -4.5 |
| SRRK | 2023-01-23 | 16.5 | 2.1 | -4.7 | -4.2 |
SRRK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SRRK has a Quality Grade of D, ranking ahead of 18.4% of graded US stocks.
- SRRK's asset turnover comes in at 0.051 -- ranking 322nd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SRRK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.051 | 1 | -0.678 |
| 2021-03-31 | 0.056 | 1 | -0.719 |
| 2020-12-31 | 0.070 | 1 | -0.841 |
| 2020-09-30 | 0.113 | 1 | -0.949 |
| 2020-06-30 | 0.119 | 1 | -0.788 |
| 2020-03-31 | 0.118 | 1 | -0.618 |
SRRK Price Target
For more insight on analysts targets of SRRK, see our SRRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $64.67 | Average Broker Recommendation | 1.3 (Strong Buy) |
SRRK Stock Price Chart Interactive Chart >
SRRK Price/Volume Stats
| Current price | $12.37 | 52-week high | $21.17 |
| Prev. close | $12.23 | 52-week low | $4.32 |
| Day low | $11.83 | Volume | 298,803 |
| Day high | $12.91 | Avg. volume | 354,486 |
| 50-day MA | $9.41 | Dividend yield | N/A |
| 200-day MA | $7.99 | Market Cap | 639.07M |
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Latest SRRK News From Around the Web
Below are the latest news stories about SCHOLAR ROCK HOLDING CORP that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023CAMBRIDGE, Mass., January 09, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023. |
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 03, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET). |
Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)Scholar Rock Holding ( NASDAQ:SRRK ) Third Quarter 2022 Results Key Financial Results Net loss: US$43.3m (loss widened... |
H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK - Research Report) today and set a price target of $30.00. The company's shares closed yesterday at $8.59.According to TipRanks, Y. Maldonado is ranked #6545 out of 8017 analysts.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Scholar Rock Holding with a $30.00 average price target.See Insiders’ Hot Stocks on TipRanks >> Based on Scholar Rock Holding's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $44 million. In comparison, last year the company earned a revenue of $4. |
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., November 15, 2022--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022. The award is subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Plan (the "Plan") and form of stoc |
SRRK Price Returns
| 1-mo | 29.12% |
| 3-mo | 49.40% |
| 6-mo | 45.53% |
| 1-year | -27.32% |
| 3-year | 0.00% |
| 5-year | N/A |
| YTD | 36.69% |
| 2022 | -63.57% |
| 2021 | -48.82% |
| 2020 | 268.21% |
| 2019 | -42.62% |
| 2018 | N/A |
Continue Researching SRRK
Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...